Medical Genome Project aims to define genetic causes of rare diseases and develop personalized therapeutics.
Roche will invest €4 million ($5.98 million) into a new Medical Genome Project in collaboration with the Junta de Andalucia Department of Health. The three-year partnership, scheduled to start next year, aims to identify the genetic causes of rare diseases and develop new therapeutics that target gene-specific disorders. The overall goal will be the development of personalized therapies tailored to individuals’ genetic makeup. The project is the brainchild of the Spanish DoH, but Roche will retain the right of first refusal to license relevant discoveries.
Hands-on research for the project will be carried out in Seville and led by researchers at the Andalusian Genetic Plan and the Andalusian Program for Genetic Research and Genomics at Cartuja 93.
